Tharimmune Announced An Option Agreement For An Exclusive License With Washington University In St. Louis For Technology Related To Multiple Hybridomas And Antibodies Directed Specifically Towards Human HER2
Tharimmune Announced An Option Agreement For An Exclusive License With Washington University In St. Louis For Technology Related To Multiple Hybridomas And Antibodies Directed Specifically Towards Human HER2
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.